Results 21 to 30 of about 212,261 (297)
Polish Journal of Pathology, 2021 Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin +4 more
doaj +1 more source
Programmed Cell Death-1/Programmed Cell Death Ligand-1 Checkpoint Inhibitors: Differences in Mechanism of Action [PDF]
Immunotherapy, 2019 Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors are widely used in many types of solid tumors, and are often considered to be in the same immunotherapy subclass. This review explores whether specific agents in these two categories exhibit differences in their mechanism of action, pharmacokinetics and ...
Ni, Zhang +3 more
openaire +2 more sources
Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]
, 2012 A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin +5 more
core +1 more source
Cancer Innovation, 2023 Background Programmed cell death‐1/ligand 1 inhibitors are a new treatment strategy for advanced urothelial carcinoma. Therefore, a comparative evaluation of their efficacy and toxicity compared with chemotherapy is necessary.
Longkun Mao +7 more
doaj +1 more source
PD-L1 Co-Stimulation Contributes to Ligand-Induced T Cell Receptor Down-Modulation on \(CD8^+\) T Cells [PDF]
, 2013 T cell receptor (TCR) down-modulation after antigen presentation is a fundamental process that regulates TCR signal transduction. Current understanding of this process is that intrinsic TCR/CD28 signal transduction leads to TCR down-modulation.
Arce, Frederick +6 more
core +1 more source
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]
, 2016 PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R. +13 more
core +21 more sources
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma [PDF]
Asian Pacific Journal of Cancer Prevention, 2019 In this era of developing targeted therapies and immunotherapies as a treatment for renal cell carcinoma (RCC), Programmed death ligand 1 (PDL1) as a novel biomarker for RCC is analysed in our study. About 90% of all renal cancers are Renal Cell Carcinoma. Most cases are diagnosed incidentally. 17% of cases are advanced at the time of diagnosis.
Chandrasekaran, Deepika +3 more
openaire +2 more sources
Chinese Medical Journal, 2020 . Historically, breast cancer has been regarded as an immunogenic “cold” tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer.
Jing Zhao, Jian Huang, Qiang Shi
doaj +1 more source
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]
, 2016 A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R +11 more
core +2 more sources
Medicine, 2021 Abstract Background: The method to evaluate the efficacy of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors has become a big concern for researchers with its widely application. Pseudoprogressive disease (PPD) makes this process more difficult, which means that the tumor progressed at ...
Jingyi Zhang +7 more
openaire +2 more sources